Plasma sRAGE and N‐(carboxymethyl) lysine in patients with CHF and/or COPD

Knowledge of the role of the receptor for advanced glycation end products (RAGE), particularly its soluble form (sRAGE), and of its advanced glycation end product (AGE) ligand, N‐(carboxymethyl)lysine adducts (CML), is limited in chronic heart failure (CHF) and in chronic obstructive pulmonary disease (COPD). We evaluated whether the AGE/RAGE system is activated in stable CHF and COPD, and whether plasma sRAGE and CML levels are affected by clinical and functional parameters.

[1]  P. Boschetto,et al.  Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure , 2013, Respirology.

[2]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[3]  L. Wood,et al.  Soluble RAGE is deficient in neutrophilic asthma and COPD , 2011, European Respiratory Journal.

[4]  R. de Caterina,et al.  Increased serum high‐mobility group box‐1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non‐diabetic patients with heart failure , 2011, European journal of heart failure.

[5]  M. Bottai,et al.  Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study , 2011, Respiratory research.

[6]  S. Raposeiras-Roubín,et al.  Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. , 2011, The American journal of cardiology.

[7]  S. Raposeiras-Roubín,et al.  Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels , 2010, European journal of heart failure.

[8]  K. Takeda,et al.  Advanced glycation end products (AGEs) activate mast cells , 2010, British journal of pharmacology.

[9]  J. Upham,et al.  Reduced soluble receptor for advanced glycation end-products in COPD , 2010, European Respiratory Journal.

[10]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[11]  M. Kawai,et al.  Influence of low-grade inflammation on plasma B-type natriuretic peptide levels. , 2010, Internal medicine.

[12]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[14]  V. Izzi,et al.  Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages , 2008, Regulatory Peptides.

[15]  I. Kubota,et al.  Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. , 2008, Journal of cardiac failure.

[16]  D. J. Veldhuisen,et al.  Advanced glycation end‐products (AGEs) and heart failure: Pathophysiology and clinical implications , 2007, European journal of heart failure.

[17]  A. Smit,et al.  Clinical and prognostic value of advanced glycation end-products in chronic heart failure. , 2007, European heart journal.

[18]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[19]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[20]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[21]  M. Cirillo,et al.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation , 2004, Heart.

[22]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[23]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  R. de Caterina,et al.  Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses , 2002, Circulation.

[25]  C. Otto,et al.  Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[26]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[27]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[29]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[30]  H. Sano,et al.  N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. , 1996, Biochemistry.

[31]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[32]  C K Wells,et al.  Evaluation of clinical methods for rating dyspnea. , 1988, Chest.